Press Release

Carl Zeiss Meditec AG records revenue growth of 7% in the first nine months 2017/18 and adjusts revenue forecast

3 July 2018

Jena/Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec (ISIN: DE0005313704) has grown revenues to around €926m in the first nine months of fiscal year 2017/18, based on preliminary data. This corresponds to a growth rate of approx. 7% against the previous year’s value of EUR 864.7 million. Currency-adjusted1 revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates. This growth amounts to around 12%.

The Company is predicting revenue totaling between €1,250 and 1,300m in the current financial year 2017/18.

The company does not currently have any other key financial figures. The 9M statement 2017/18 will be published on August 10, 2018.

Press & Investor Relations Contact

Sebastian Frericks

Director Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

 


Share this article

  • 1

    Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.